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Introduction
Cystitis, infection of the bladder, is responsible for c. 95%
of all symptomatic urinary tract infections (UTI; Muhl-
dorfer et al. 2001), which is one of the most prevalent
infectious diseases. A population-based survey in 1995
estimated that annually between 7Æ3 and 11 million
women in the United States of America had at least one
presumed UTI treated with an antibiotic (Foxman et al.
2000). An estimated 130–175 million cases of UTI occur
annually worldwide with huge social costs, and evaluation
and management of UTI approximates US$1Æ6 billion
(Foxman 2002). The figures can be higher if costs of self-
diagnosed and self-medicated infections (Hooton and
Stamm 1997; Gupta and Hooton 2004) are taken into
account.
UTI is considered to be uncomplicated when it occurs
in patients with urinary tracts that are normal from both
a structural and functional perspective or complicated
when it occurs in other settings (Hooton 2000; Cohn and
Schaeffer 2004). Even episodes of acute uncomplicated
cystitis are associated with considerable morbidity, includ-
ing an average of 6Æ1 days of symptoms, 2Æ4 days of
restricted activity and 0Æ4 bed days (Foxman and Frerichs
1985a,b).
Asymptomatic bacteriuria or asymptomatic urinary
infection is defined as the presence of a specified quantity
of bacteria in an appropriately collected urine specimen
obtained from a person without symptoms or signs refer-
able to urinary infection (Nicolle et al. 2005). Asymptom-
atic bacteriuria is common, but the prevalence in
populations varies widely with age, sex and other host
factors.
Overview of the pathogenesis of UTI
The urinary tract consists of paired organs, the kidneys
and two ureters, a bladder and a urethra. The urinary
bladder is a muscular organ, hollow and roughly spheri-
cal-shaped when filled with urine. The mucosa of the
renal pelvis, ureter and urinary bladder is lined by strati-
fied epithelium, the urothelium. Cuboidal-to-columnar
cells form the basal layer and the superficial layer is made
up of relatively large cells, which may take on an
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Abstract
In a time when conventional antibiotics are becoming increasingly less effective
for treatment of infections, the relationship between bacteria and antimicrobial
resistance is becoming more and more complicated. This paper provides a cur-
rent review of studies reported in the literature pertaining to the antibiotherapy
of human urinary tract infections (UTI), in a way that helps the reader direct a
bibliographic search and develop an integrated perspective of the subject. High-
lights are given to (bio)pathogenesis of uncomplicated cystitis. Features associ-
ated with the antibiotherapy of UTI such as development of resistance are
presented in the text systematically. This review discusses recent advances in
the understanding of how the predominant uropathogen Escherichia coli inter-
acts with its host and leads to infection; so one can understand some of the
reasons behind antibiotherapy failures.
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‘umbrella-like’ shape owing to their outer convex shape.
The urothelium also acts as an active component of the
innate immune system, through the production of cyto-
kines, chemokines and secretory immunoglobulin A, sIgA
(Mulvey et al. 2001; Vaidyanathan et al. 2002).
Uropathogens can enter the urinary tract and cause
UTI via the ascending route or the haematogenous
route. The vast majority of UTI are thought to occur
via the ascending route, and bladder infections are
much more common than kidney infections (Hooton
2000; Scholes et al. 2005). Vaginal colonization is con-
sidered to be a prerequisite to bladder infection in
women (Stamey and Sexton 1975). Sometimes, these
ascending uropathogens reach the kidney and can cause
pyelonephritis (in 5% of all UTI). The mechanism of
ascension is uncertain, but motility mediated by flagella
and pili appears to be important (Wright et al. 2005;
Lane et al. 2007). Risk factors for pyelonephritis are
similar to those for cystitis, including sexual inter-
course, and genetic factors may play a role (Scholes
et al. 2005; Rama et al. 2005).
Uropathogenic Escherichia coli (UPEC) cause 70–95%
of all uncomplicated UTI (Hooton 2000) and 50% of
healthcare-associated UTI (Hooton and Stamm 1997;
Ronald 2002; Cohn and Schaeffer 2004). Other uropatho-
gens causing uncomplicated UTI include Staphylococcus
saprophyticus in 5–10%, and Klebsiella pneumoniae, Pro-
teus mirabilis, group B streptococcus, and other bacteria,
in less than 5% (Ronald 2002; Nicolle 2003).
Advances in cellular and molecular biology have
improved the understanding of the micro-organism–host
association, but much is still unknown. It is clear, how-
ever, that the strain pathotype is an important determi-
nant of uropathogenicity (Johnson and Russo 2005).
Strain pathotypes are characterized by sets of virulence
factors that facilitate certain pathogenesis processes
(Bekal et al. 2003; Marrs et al. 2005; Guy 2006). The
virulence factors of UPEC are specific properties that
confer on bacteria the ability to adhere to the urinary
tract, persist and invade the host tissues causing injury
(Johnson et al. 2005; Rama et al. 2005). Such factors
also result in avoidance of host defence mechanisms
and ⁄or stimulation of a host inflammatory response
(Johnson and Stell 2000). UPEC isolated from patients
with UTI possess substantially more virulence factors
(VF) on average compared with commensal faecal iso-
lates (Johnson et al. 2005). The former typically carry
large blocks of genes, called pathogenicity-associated
islands (PAI), not generally found in commensal faecal
isolates and are known to contribute to the pathogenic-
ity of bacteria and their resistance to antibiotics (Hacker
and Kaper 2000; Guyer et al. 2002; Johnson and Russo
2005). PAI were first described in the human pathogen
E. coli (Hacker and Kaper 2000; Dobrindt et al. 2004).
PAI encode a wide range of bacterial virulence factors
from adhesins to toxins to host defence avoidance
mechanisms (Hacker and Kaper 2000). For example, P
fimbriae, which represent important adherence factors of
UPEC, are encoded by UPEC-specific PAI. P-fimbrial
genes (pap or prs) are often linked to gene clusters hly
and cfn, respectively encoding the UPEC-specific toxins
a-hemolysin and cytotoxic necrotizing factor 1, a linkage
that argues for a strong co-evolution of these factors
(Hacker and Kaper 2000). Moreover, some genes in
plasmids and prophages help bacteria to increase their
pathogenicity to a mammalian host. A very good exam-
ple is the bor gene of lambda bacteriophage that confers
protection of the bacterial host against serum
complement killing (Koch 2007).
The boundary between commensalism and virulence
results from a complex balance between the status of the
host and the presence and expression of virulence factors
in the bacteria (Picard et al. 1999).
UPEC attachment to the uroplakins of the host tissue
uroepithelium constitutes the first step in the colonization
of their hosts by the mannose-sensitive binding of fila-
mentous fimbria. FimH is the adhesin present at the tip
of type 1 pili that binds to the mannose-containing glyco-
protein receptors expressed on the luminal surface of the
bladder (Sussman and Gally 1999; Hung et al. 2002).
Studies using mice models have shown that instead of
being confined to the lumen of the bladder, UPEC rapidly
gain access to the urothelium and are quickly internalized
where they proliferate in an intracellular sanctuary. The
internalization of adherent UPEC through the FimH
adhesin stimulates host cell signalling cascades and leads
to the induction of cytoskeletal rearrangements (Mulvey
et al. 2001). The resulting intracellular bacterial commu-
nity (IBC) has biofilm-like properties that protect it from
the host’s innate immune response (Anderson et al. 2004;
Wright et al. 2005) and is inherently tolerant to antibiotics
(Cerca et al. 2005). Eventually, these IBC detach from the
biofilm and disperse themselves into the bladder lumen,
resulting in the spread of the bacteria over the epithelial
surface, to initiate additional rounds of IBC formation
(Anderson et al. 2004; Wright et al. 2005; Garofalo et al.
2007), in a manner reminiscent of a lytic virus cycle
(Mulvey et al. 2001; Justice et al. 2004; Wright et al. 2005).
Re-entry of detached bacteria into the IBC developmental
cascade is marked by slower kinetics (Franco 2005; Wright
et al. 2005). At this point, bacterial replication ceases and a
quiescent reservoir or persistent state is established in the
bladder tissue that, in response to nutrient and oxygen
limitations in the interior of the microcolonies, can
reactivate and trigger a recurrent ⁄persistent bacteriuria
(Corbin et al. 2001; Wright et al. 2005).
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In the mouse model, IBC protect UPEC from: (i)
innate host defences, such as phagocytosis and clearance
by micturition, and (ii) antibiotic treatment. The IBC cas-
cade has not been demonstrated in humans, but a
recently published paper demonstrates evidence of IBC-
like structures in exfoliated uroepithelial cells of women
with acute cystitis (Rosen et al. 2007).
Micro-organism VF
Virulence is defined as the ability of an organism to
cause disease in a particular host (Rama et al. 2005).
VF help determine whether or not a strain can invade
the host and allow for the survival of an organism in
less propitious environments, as urine can be. A variety
of virulence genes that encode VF are associated
with UPEC (see Table 1), which possess substantially
more VF than faecal E. coli isolates (Johnson et al.
2005). Uropathogenic strains are highly adapted and
possess many factors that facilitate bladder colonization
and survival in the urinary tract, and often the ability
to cause tissue damage (Sussman and Gally 1999). In
particular, UPEC infecting young men tend to be highly
virulent (Hacker and Kaper 2000; Johnson and Stell
2000; Johnson et al. 2005). Table 1 shows the wide
diversity of some of the important VF found in
UPEC, together with important features associated
therewith.
Bacterial adhesins are important and provide UPEC
with the ability to adhere to the uroepithelium. Cyto-
lethal distending toxin causes damage to the host. Haemo-
lysin and k-antigen promote phagocytosis. Extracellular
Table 1 Diversity of some of the important virulence factors (VF) found in uropathogenic Escherichia coli
VF Characteristics References
Adhesins Serve as ligands for glycoproteins and glycolipids
on the surface of uroepithelial cells; prerequisite
for penetration of invasive organisms
Rama et al. 2005
Pathogenicity-associated
islands (PAI)
Genetically linked VF Johnson and Russo 2005
SPATE (serine protease
autotransporters of
Enterobacteriaceae) –
secreted autotransporter
toxin (Sat)
A cytotoxin for bladder and kidney epithelial cells Guyer et al. 2002
Haemolysin Secreted by haemolytic E. coli: (i) lyses human erythrocytes;
(ii) contributes to inflammation; (iii) causes tissue injury;
and (iv) weakens chemotaxis and phagocytosis
Rama et al. 2005
Siderophores – aerobactin
and enterochelins
Extracts iron from the host for metabolic activities Rama et al. 2005
traT gene Confers resistance to serum bactericidal activity Kanukollu et al. 1985
Lipopolysaccharide (LPS)
somatic antigen (O-antigen)
Highly immunogenic endotoxin that activates complement
via alternate pathway-releasing cytokines, chemokines, etc.,
leading to an acute inflammatory response
Rama et al. 2005
Capsular polysaccharide
(K-antigen)
Interferes with O-antigen detection, protecting the bacterium
against phagocytosis; poorly immunogenic
Rama et al. 2005
Cytotoxic necrotizing factor
types 1 and 2 (CNF 1 ⁄ 2)
Members of the family of bacterial toxins that target the
Rho family of small GTP-binding proteins
Schmitt et al. 1999
Cytolethal distending toxin Causes progressive cell distending leading to cell death by
direct DNA damage of host cells
Mulvey et al. 2001
P-fimbriae The most important and widely studied mannose-resistant
adhesins of uropathogenic E. coli. These fimbriae bind
to the host cells through galactosyl (a,1-4)-galactose-
b-dissacharide galbiose receptors, which are part of the
P blood group system antigens. P-fimbriated strains are
associated with more clinically severe infections
Rama et al. 2005
Type-I fimbriae Mediate mannose-sensitive bacterial attachment to the bladder
epithelium via interaction with glycoproteins rich in D-mannose.
Type-I fimbriae bind to Tamm-Horsfall-proteins (THP), which
often coat uroepithelial cells and prevents bacterial adherence
to the urinary mucosa and facilitate the expulsion of bacteria
Rama et al. 2005
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generation of reactive oxygen species (ROS) is induced
by bacterial strains that resist ingestion by phagocytes
(Rama et al. 2005). Sat is a serine protease that promotes
cytopathic effects similar to those inducing vacuolization
within the cytoplasm of the human urinary tract (Guyer
et al. 2002). It is the only known vacuolating toxin of
E. coli strains isolated in human urine. Recently, it has
been classified as a member of the Serine Protease Auto-
Transporter of the Enterobacteriaceae (SPATE) family.
All phenotypes associated with the SPATE proteins
enable bacteria to damage the host and evade the
immune response (Guyer et al. 2002).
Environmental factors
The urinary tract is an ecological niche where structural,
functional and physiological factors play a role in the
genesis of infection. Urine is a good bacterial broth with
physiological values of pH and osmolarity allowing for
rapid bacterial growth. Human urine can promote the
growth of UPEC bacteria as its composition includes a
variety of nutrients (e.g. glucose, amino acids and uric
acid), but it is a poor source of iron (Schwan et al. 2002).
However, other components of urine, such as urea and
organic acids, may inhibit microbial growth when in high
concentrations (Sussman and Gally 1999). Although little
is known about the environmental regulation of bacterial
toxin production in the urinary tract, haemolysin expres-
sion in E. coli appears to respond to osmolarity, tempera-
ture and anaerobic conditions (Sussman and Gally 1999).
Host factors
Sexual intercourse is one of the most important risk fac-
tors associated with the risk of uncomplicated UTI (Hoo-
ton 2000). In uncomplicated UTI, anatomy plays an
important role with respect to the large difference
between men and women in UTI risk. The drier environ-
ment surrounding the male urethra, especially with cir-
cumcision, prevents the optimal growth of bacteria
compared with the female urethra. The antibacterial acti-
vity of prostatic secretions in men is also a factor that
reduces the risk of UTI in men. In men, there is also a
much longer distance between the anus and the urethral
meatus (Hooton 2000). Genital microflora plays an
important role in women’s defenses against invasions, so
any alterations (e.g. due to antibiotherapy and its adverse
effects upon the genital ecology) can enhance genital col-
onization with uropathogens and risk of subsequent UTI
(Hooton 2000).
Host factors such as the epithelial cell receptivity are
also important in the onset of infection (Table 2). For
example, E. coli binds to vaginal epithelial cells from
healthy controls less avidly than to vaginal epithelial cells
from women with recurrent UTI (Cohn and Schaeffer
2004). Vaginal cell receptivity also varies as a function of
hormonal status. Bacterial adherence tends to be higher
earlier in the menstrual cycle and in postmenopausal
women as compared with the pre- women or postmeno-
pausal women who are on oestrogen replacement therapy
(Cohn and Schaeffer 2004) predisposing them to recur-
rent UTI (Franco 2005). Presence of diabetes mellitus has
been shown to enhance the frequency of recurrent UTI
by two- to threefold (Franco 2005). Several approaches
can be employed to prevent recurrences of UTI: long-
term prophylaxis, postcoital therapy and patient-initiated
therapy (Franco 2005).
Determinants of host response to therapy
There are numerous reasons why a patient may not
respond to antibiotic therapy, many of which are related
to the inappropriate selection of antibiotics for treating
UTI (Nicolle 2001). For example, in men with UTI, infec-
tion of the prostate requires treatment with antimicrobials
that penetrate the prostate. In patients with upper tract
infection, nitrofurantoin is inappropriate because it does
not achieve adequate tissue concentrations.
Determinants of bacterial response to therapy
Antibiotic resistance complicates the treatment of UTI
and is associated with a higher patient morbidity, higher
costs of re-evaluation and re-treatment, higher rates of
hospitalization and greater use of broader-spectrum
antibiotics (Hooton et al. 2004). The selective pressure
promoted by antimicrobial drugs in the various environ-
mental settings such as nursing homes, hospitals and
long-term care facilities, contributes for the selection and
spread of resistant clones.
A population of organisms can lose its sensitivity to an
antibiotic while the patient is under treatment. The devel-
opment of new antimicrobial drugs has counterbalanced
this trend. However, we are currently approaching a micro-
bial resistance level never attained before, which might
pose a serious risk to the effectiveness of the current antibi-
otic treatments in the near future (Wagenlehner and Naber
2006). An understanding of the mechanisms by which uro-
pathogenic micro-organisms manifest resistance to antimi-
crobials (both intrinsic and acquired resistances) is
necessary to optimize treatment strategies for UTI.
Intrinsic resistance
Intrinsic resistance is an inherent insensitivity of the
bacterium to the antibiotic action. Some gram-negative
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bacteria, including Enterobacteriaceae exhibit intrinsic
resistance to cephalosporins by producing AmpC b-lacta-
mases (Martinez et al. 1998). Another example is the
intrinsic resistance of Pseudomonas to benzylpenicillin.
Acquired resistance
Acquired resistance represents a major threat to human
health because of its high prevalence in major pathogens
causing human diseases (Table 3). Acquired resistance is
mainly because of: (i) a genetic change in the bacterial
genome, which can be the consequence of a mutation of
chromosomal target genes, or (ii) exogenous resistance
acquired from horizontal acquisition of foreign resistance
genes.
Horizontally transferable resistance is because of trans-
fer of: (i) plasmids (R-factor), (ii) integrons and gene
cassettes, (iii) bacteriophages, as a prophage (Tinsley et al.
2006) and (iv) chromosomal genomic islands, which play
a major role in the horizontal transfer of antimicrobial
resistance to one or more antimicrobial drugs.
Studies indicate that uropathogens are becoming
increasingly resistant to the antibiotics used for the treat-
ment of UTI. As an example, SENTRY, an Antimicrobial
Table 2 Host susceptibility factors that promote urinary tract infection (UTI)
References
Gender Women Pregnancy Nicolle et al. 2005
Sexual activity Foxman et al. 2000;
Nicolle et al. 2005;
Nicolle 2001
Oestrogen deficiency in
postmenopausal women
Cohn and
Schaeffer 2004
Genetic predisposition to urinary tract
infection – vaginal cell receptivity
Men: obstructive
uropathy in older men
Nicolle et al. 2005
Age Middle-age: higher
incidence in women aged
25–50 years,
due to sexual activity
Indwelling catheters Chronic indwelling
catheters
Use of a long-term indwelling catheter
is associated with bacteriuria virtually 100%
of the time
Nicolle et al. 2005
Acute indwelling
catheters
While catheter remains in situ bacteriuria
is acquired at the rate of 2–7% per day
Nicolle et al. 2005
Encrustation of biomaterials employed in the urinary tract is a
major problem resulting in the obstruction or blockage of catheters
or stents
Tunney et al. 1997
Diabetics Women: bacteriuria is more common in diabetic women, with a prev-
alence of 8–14%, and is usually correlated with duration of diabetics
and presence of long-term complications of diabetics
Nicolle 2005
Men: diabetic men do not appear to have an increased prevalence
of bacteriuria, compared with nondiabetic men
Nicolle 2005
Sexual intercourse The prevalence of bacteriuria among young women is strongly
associated with sexual activity
Foxman et al. 2000;
Hooton 2000; Johnson et al. 2005
Patients with spinal
cord injuries
Neurogenic bladder with chronic or intermittent catheterization Ronald 2002; Nicolle et al. 2005
Increase in renal ⁄
bladder ⁄ prostatic
calculi
Causing prostatic hypertrophy and fluxing disorders like
turbulent urine flow and urethral obstruction
Nicolle 2001
Iatrogenic genitourinary
instrumentation
Women: application of diaphragm Russell and Love 1991
Cystourethroscopy Franco 2005
Care units Nosocomial environment
Birth control methods Oral contraceptives or condoms and diaphragms or cervical caps
had a significantly higher incidence of risk of reinfection
Foxman et al. 2000
Antibiotic use in the
previous 2 weeks of a UTI
Women who reported taking antibiotics during 2 weeks prior
to the follow-up survey had a higher rate of second UTI
Foxman et al. 2000;
Nicolle et al. 2005; Franco 2005
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Surveillance Program that monitored UTI worldwide over
a 4-year period between 1997 and 2000 (Turnidge et al.
2002), showed an increase in resistance among UTI iso-
lates (Turnidge et al. 2002). The frequency of detection of
extended-spectrum b-lactamases (ESBL)-producing strains
(including E. coli) is quite variable but is consistently
increasing (Sader et al. 1994). The growing levels of resis-
tances to broad-spectrum antibiotics such as fluoroqui-
nolones is recognized as a significant problem in some
medical centres and some clinical studies have docu-
mented this problem throughout the world (Gales et al.
2000).
Strains of community-acquired ESBL causing UTI are
often multidrug-resistant, which complicates treatment
and are often not detected early (Paterson 2006). The
extent of ESBL-producing strains including E. coli is quite
variable between medical centres and this most likely is
related to differing prescription practices and ⁄or infection
control practices that can lead to the spread of resistant
clones and can in turn spread resistance, through gene
transfer, to other related species (Sader et al. 1994; Pitout
et al. 1998; Turnidge et al. 2002).
Antimicrobial therapy in uncomplicated UTI
The goal of treatment of an uncomplicated UTI is the
resolution of symptoms and sterilization of the urine.
Antimicrobial drugs used for UTI therapy should have
certain characteristics: (i) they should be active against
the most common uropathogens; (ii) they should be
excreted in the active form of drug by glomerular filtra-
tion into urine; (iii) they should have both adequate con-
centrations and inhibitory levels in urine (and tissue
when treating pyelonephritis); and (iv) they should be
active at urinary pH values. Sulfametoxazol-trimethoprim,
fluoroquinolones, b-lactams, nitrofurantoin and fosfomy-
cin are the most common antimicrobial agents used in
the therapy of UTI (Karlowicz 1997; Gupta et al. 2001).
Of note, susceptibility breakpoints from the Clinical and
Laboratory Standards Institute (CLSI, formerly NCCLS)
are based on serum rather than urine concentrations of
these antimicrobial agents, except for nitrofurantoin and
fosfomycin, which are exclusively used for treatment of
cystitis.
Human studies have shown that sulfametoxazol-
trimethoprim is less effective against sulfametoxazol-
trimethoprim-resistant uropathogens causing cystitis
(Gupta et al. 2007) or pyelonephritis (Talan et al. 2000).
Sulfametoxazol-trimethoprim
Sulfonamides and trimethoprim, also called co-trimoxa-
zole, inhibit the synthesis of tetrahydrofolic acid, which is
necessary for DNA synthesis in bacteria. Sulfonamides are
structural analogues of the normal substrate p-aminoben-
zoic acid. The enzyme dihydropteroate synthase (dhps),
an essential enzyme in all living cells, catalyses the forma-
tion of dihydropteroic acid in bacteria, a step before tet-
rahydrofolic acid formation. Sulfonamides act as
competitive inhibitors of dhps, thereby blocking tetrahy-
drofolic acid biosynthesis in the bacterial cell. Trimetho-
prim is a structural analogue of tetrahydrofolic acid and
competitively inhibits the reduction of dihydrofolate to
tetrahydrofolate by dihydrofolate reductase (dhfr). As bac-
teria are unable to take up folic acid from the environ-
ment and are thus dependent on their own de novo
synthesis, inhibition of folic acid synthesis prevents DNA
replication in the bacteria.
Only three genes encoding resistance to sulfonamides
are known – SulI, SulII and Sul3 – and the most recent
one was discovered only 3 years ago (Guerra et al. 2004)
(please see Table 3). Mutational changes in the chromo-
somal gene folP that encodes dihydropteroate synthase
results in a lowered affinity for sulfonamide (Skold 2001;
Fiebelkorn et al. 2005). There were 111 altered nucleo-
tides resulting in 30 amino acid changes when folP in
susceptible and resistant strains were compared (Skold
2001).
Chromosomal resistance to trimethoprim can be
because of mutational changes in the intrinsic dihydro-
folate reductase dhfr gene. Dihydrofolate reductase
converts dihydrofolate into tetrahydrofolate, a methyl
group shuttle required for the de novo synthesis of
purines, thymidylic acid and certain amino acids.
Trimethoprim resistance in the 1970s rarely occurred
in more than 10% of the UPEC isolates, but in the 1980s
increased to 15–20%, with the exception of South Amer-
ica, Asia and Africa where levels of 25–68% were reported
(Urbina et al. 1989; Wylie and Koornhof 1989; Lamikanra
and Ndep 1989).
Guidelines published in 1999 by the Infectious Diseases
Society of America (IDSA) recommend sulfametoxazol-
trimethoprim as the first-line treatment for acute cystitis.
There are numerous other UTI treatment guidelines
worldwide that also list sulfametoxazol-trimethoprim as
the drug of choice for first-line therapy of acute cystitis.
However, resistance to sulfametoxazol-trimethoprim has
been increasing, raising concerns about its role as a first-
line agent for UTI treatment (Hooton et al. 2004; Karaca
et al. 2005), and leading some clinicians to consider sul-
fametoxazol-trimethoprim as a first-line agent only in
women who do not have underlying risk factors such as
older age or diabetes (Gupta et al. 2001).
A European survey of a well-defined population of
women with acute uncomplicated cystitis (the ECO-
SENS Project, conducted during 1999–2000) found
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sulfametoxazol-trimethoprim resistance in 9–15% of the
E. coli isolates in all countries with the exception of Spain
and Portugal, where the rate was nearly 35% (Kahlmeter
2003). Over the last decade, the treatment of choice for
UTI in Turkey has changed from sulfametoxazol-trimetho-
prim to fluoroquinolones owing to the rate of resistance
to cotrimoxazole and its high level of therapeutic failure
(Karaca et al. 2005).
The increase in prevalence of sulfametoxazol-trimetho-
prim resistance among UPEC in the United States is in
part related to clonal spread. Clusters of UTI-causing uro-
pathogen clones were identified during the investigation
of antibiotic-resistant strains, as they exhibit an concur-
rent resistance to ampicillin, chloramphenicol, streptomy-
cin, sulfonamides, tetracycline and trimethoprim
(ACSSuTTp; Johnson et al. 2002). It is possible that many
community-acquired UTI occur in epidemiologically
linked clusters that are not identified, because urine cul-
tures are often not performed for cystitis and isolates
and, when present, are not genotyped or serotyped (Hoo-
ton and Samadpour 2005).
Quinolones
Quinolone drugs are bactericidal compounds that act by
interfering with DNA and RNA synthesis, and fluoroqui-
nolones inhibit DNA synthesis by inhibiting DNA gyrase,
interfering with DNA replication, repair and transcription
before ultimately causing bacterial cell death (Karlowicz
1997; Bearden and Danziger 2001). In gram-negative
organisms, DNA gyrase is the primary target, whereas in
gram-positive bacteria, topoisomerase IV was recently
found to be most affected (Bearden and Danziger 2001).
The first clinically available quinolone, nalidixic acid,
penetrated poorly into the tissues, and was used only for
the therapy of gram-negative UTI. Several newer fluoro-
quinolones have broader spectrum of activity and more
optimal tissue levels and, thus, are used for a wide variety
of both uncomplicated and complicated infections. How-
ever, the use of fluoroquinolones is contraindicated in
pregnant women and children or adolescents, because of
potential damage in cartilage formation, high-perfor-
mance athletes, as they can cause tendonitis and rupture
of the Achilles tendon even after a short-term use; and
patients with QT interval prolongation or pre-existing
rhythm disorders. Although, as a class, fluoroquinolones
are not nephrotoxic, their dosage must be adjusted when
administered to patients with renal failure.
Fluoroquinolones are often considered agents of first
choice in patients with UTI because of the increasing preva-
lence of resistance of E. coli to sulfametoxazol-trimetho-
prim. Ciprofloxacin, levofloxacin and norfloxacin are
increasingly being used, even in uncomplicated UTI. Cip-
rofloxacin can often be considered the first-choice antimi-
crobial in UTI patients with allergies to other drugs, in the
elderly, in patients with recurrent infections and in diab-
etics (Schilling et al. 2002; Hooton 2003a). However,
increasing fluoroquinolone resistance is a serious public
health threat, and it is essential that the indiscriminate use
of these agents is avoided, if we are to preserve the efficacy
of these drugs to critical diseases. For example, the preva-
lence of fluoroquinolone resistance in UPEC causing
uncomplicated UTI is very high in some parts of the world,
especially in southern Europe, where it has been reported
to be as high as 20% (Kahlmeter 2003).
Fluoroquinolone resistance in Enterobacteriaceae is
most frequently caused by chromosomal mutations. More
recently, however, plasmid-mediated quinolone resistance
has emerged in E. coli. The emergence of this new plas-
mid-mediated quinolone resistance provides a mechanism
for the rapid spread of quinolone and multidrug resis-
tance to important members of the Enterobacteriaceae
(Hooton 2003b; Paterson 2006).
Given concerns that increasingly widespread use of
fluoroquinolones will promote bacterial resistance, their
use for the routine treatment of acute uncomplicated
cystitis should be discouraged (Kahlmeter 2003; Hooton
et al. 2004; Gupta et al. 2005).
b-lactams
All b-lactams produce their bactericidal effects via inhibi-
tion of bacterial cell wall synthesis (Karlowicz 1997).
Aminopenicillins
Ampicillin and amoxicillin have been extensively used in
the therapy of cystitis. However, the increased prevalence
of resistance of uropathogens to this class of drugs, pri-
marily via b-lactamase production has resulted in
decreased usage. b-lactamase is an enzyme produced by
some bacteria that inactivates b-lactam antibiotics.
Plasmidic b-lactamases are widespread and, of these,
TEM-1 is present in 40% of all gram-negative bacterial
isolates. The activity of amoxicillin ⁄ clavulanic acid against
E. coli greatly depends on the level of b-lactamase pro-
duction by the strain. Thus, it is necessary to obtain
in vivo concentrations of clavulanic acid at sufficient
concentrations that inhibit b-lactamase production by
E. coli at the infection site (Ponte et al. 2005).
In recent studies, the prevalence of resistance to ampi-
cillin has ranged from 26% to 38% in the United States
(Paterson 2006). The ECO.SENS study showed that E. coli
is now resistant to ampicillin in more than 40% of all
cases in Spain, Portugal, Ireland and Luxembourg (Kahl-
meter 2003). Moreover, the number of UPEC strains dis-
playing intermediate resistance to amoxicillin ⁄ clavulanic
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acid might be increasing, which could have important
detrimental consequences in countries such as Spain,
where the rates of resistance of E. coli to fluoroquinolones
is as high as 22Æ8% from community-acquired UTI
isolates (Hooton 2003b; Ponte et al. 2005). Candida vagi-
nitis is common secondary to the use of aminopenicillins.
Amoxicillin ⁄ clavulanic acid has greater activity against
resistant UPEC strains, but is more expensive and pro-
duces more side effects (such as predisposing the patient
for relapses) because these antibiotics greatly alter the
normal genital microflora (Hooton 2000). In addition,
amoxicillin-clavulanate does not perform, as well as fluor-
oquinolones, for the treatment of uncomplicated cystitis,
even in patients infected with strains susceptible to the
drug (Hooton et al. 2005).
Cephalosporins
Activity of cephalosporins against E. coli increases from
the first to the fourth generation of these drugs, but the
newer classes are more expensive and there are fewer oral
alternatives. However, the number of resistant strains to
cephalosporins has been increasing recently (Ribeiro et al.
2002). Enterobacteriaceae resistance to third-generation
cephalosporins is because of the production of b-lacta-
mases (Paterson 2006). According to the National Noso-
comial Infections Surveillance (NNIS) System report in
2003, 5Æ8% of E. coli isolated from patients in intensive
care units in the United States, were nonsusceptible to
third-generation cephalosporins owing to the production
of b-lactamases (Paterson 2006). Cephalosporins are a
useful option for the treatment of uncomplicated UTI
during pregnancy because of their safety (Nicolle 1996).
Amidinopenicilins
Pivmecillinam is the pro-drug of mecillinam, a penicilin
analogue that differs from other b-lactams in that the
b-lactam ring is linked to the side chain by an amidino
instead of an amindo group (Anderson et al. 1976). It
possesses activity against gram-negative micro-organisms
such as E. coli and other Enterobacteriaceae (Graninger
2003), and has higher activity when compared with
amoxicillin (Anderson et al. 1976). Mecillinam binds only
to PBP2 of gram-negative bacilli leading to cell lysis. A
study conducted in 16 European countries and Canada
found a resistance of E. coli of 1Æ2% (Kahlmeter 2003).
The high and increasing levels of resistance among E. coli
to currently recommended first-line agents for acute cysti-
tis requires a re-evaluation of treatment guidelines. With
a low prevalence of resistance, good efficacy (Ferry et al.
2007) and not having major effects on the anaerobic
intestinal microflora (Edlund and Nord 2000), pivmecilli-
nam is a suitable first-line agent for empirical treatment
of acute cystitis.
Nitrofurantoin
Nitrofurantoin has been in clinical use for more than
50 years now, and because antimicrobial levels are not
attained in the blood its only indication is for uncompli-
cated cystitis (Hooton 2003a). It is readily absorbed from
the gastrointestinal tract and rapidly excreted by the
kidneys. Its mechanism of action is inhibition of bacterial
acetyl coenzyme A with the disruption of cell wall
formation (Karlowicz 1997). Nitrofurantoin is reduced by
bacterial flavoproteins to reactive intermediates, which
inactivate or alter bacterial ribosomal proteins and other
macromolecules. This inactivation or alteration of bacte-
rial ribosomal proteins and macromolecules inhibits aero-
bic metabolism and, as a result, the syntheses of bacterial
deoxyribonucleic acid (DNA), ribonucleic acid (RNA), cell
wall and protein. This antibiotic has maintained excellent
activity against almost all E. coli strains causing uncompli-
cated UTI, but some uropathogens, such as Proteus and
Klebsiella are resistant. Nitrofurantoin does not appear in
measurable amounts in the stool and, consequently, com-
mensal flora remain unaffected. Moreover, it has recently
been shown to be as effective in a 5-day course as sul-
fametoxazol-trimethoprim in a 3-day course for the treat-
ment of uncomplicated cystitis (Gupta and Hooton 2004).
Nitrofurantoin should therefore be considered as a fluor-
oquinolone-sparing alternative to sulfametoxazol-trimeth-
oprim for uncomplicated cystitis (Hooton et al. 2004).
There is some concern regarding the safety of nitrofuran-
toin, because of acute or chronic pulmonary syndromes,
but these are rarely seen with short-course regimens used
for treatment of uncomplicated UTI (Hooton 2003a).
Fosfomycin
Fosfomycin is a phosphoenolpyruvate analogue that
irreversibly inhibits enolpyruvate transferase (MurA),
which prevents the formation of N-acetylmuramic acid,
an essential element of the peptidoglycan cell wall.
Fosfomycin penetrates into the cells through a system of
permeases; any mutation on these permeases can prevent
the antibiotic from penetrating the cell. Fosfomycin shows
reduced activity at pH >6Æ4. Resistance to fosfomycin is
because of several mechanisms, both chromosomal- and
plasmid-borne. Chromosomic resistance can be because
of the production of a constitutive enzyme (fosfomycin-
glutation-S-transferase) that inactivates the antibiotic in
the periplasm. Plasmid-mediated resistance is to the result
of enzymatic modifications of the antibiotic (Llaneza
et al. 1985) A 3-g sachet dose is generally effective and
well tolerated, with diarrhoea being the most common
side effect. Fosfomycin is moderately active against E. coli
strains and many other uropathogenic micro-organisms
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that cause uncomplicated UTI. Urinary levels persist over
48 h, but bacterial resistance may develop quickly.
Fosfomycin therapy is one of the most expensive antibio-
therapies (Hooton et al. 2004).
Conclusions
The increasing frequency of bacterial drug resistance has
been attributed to combinations of microbial characteris-
tics, selective pressure of antimicrobial use and both
social and technological changes that enhance the trans-
mission of drug-resistant micro-organisms. The overall
increase in the life expectancy of human beings and, con-
sequently, of the number of persons with problematic
clinical conditions such as the use of urinary catheters
and chronic underlying diseases such as cancer, renal
insufficiency, immunocompromised (HIV) status and dia-
betes, have led to a growing number of persons at risk
for developing UTI. Prevention and control of bacterial
resistance will require new antimicrobial agents, the pru-
dent use of existing ones, new vaccines and enhanced
public health efforts to reduce transmission of bacterial
resistance.
Antimicrobial treatment of UTI has changed markedly
over the last decade. The emergence of bacterial resistance
suggests the need for an emphasis on understanding the
local patterns of drug resistance, avoiding fluoroquino-
lones as much as possible to reduce risk of resistance,
using sulfametoxazol-trimethoprim as the first-line treat-
ment unless the patient has risk factors to suggest resis-
tance and, e.g. by using more nitrofurantoin as a
fluoroquinolone-sparing agent for uncomplicated cystitis.
Future perspectives
Increasing resistance to first-line antibiotics, particularly
sulfametoxazol-trimethoprim, has progressively compli-
cated the management of UTI, therefore urging revised
treatment approaches. Tailoring the principles reviewed
here to individual patients can help the practicing clinician
in meeting these challenges. Considerable effort has to be
devoted towards reducing the emergence of micro-organ-
isms resistant to antimicrobial drugs, to simplify manage-
ment, to improve the cost-effectiveness of treatments and
to enhance the patient’s compliance to the treatment by
investigating the efficacy of alternative treatments.
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